![\"Forum](\"https:\/\/clixtrac.com\/banner\/318671.jpg\" "\\"Forum")
<\/a>\r\n<\/div><\/p>\n<\/div><\/section><\/div>![\"\"](\"https:\/\/clixtrac.com\/banner\/283809.png\" "\\"\\"")
<\/a>\r\n<\/div><\/p>\n<\/div><\/section>\n
Revvity introduces first dried blood spot-validated measles antibody test with CE mark<\/h1>Product News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\nRevvity\u2019s EUROIMMUN has received CE marking for its Anti-Measles Virus ELISA 2.0 (IgG), the first commercial assay validated for dried blood spot (DBS) sample material, addressing a critical gap in measles diagnostics as global cases continue to rise.<\/h3>\n
<\/p>\n
Innovation in sample collection<\/h4>\nThe newly launched Anti-Measles Virus ELISA 2.0 (IgG) represents a significant advancement in measles diagnostics, particularly for resource-limited settings. This IVDR-compliant solution supports both the diagnosis of measles virus infection and determination of immune status against the virus.<\/p>\n
The assay\u2019s key innovation lies in its validation for dried blood spots as a sample material, alongside conventional serum and plasma samples. DBS sampling requires only droplets of capillary blood from a fingertip, deposited onto a paper card, which can then be transported to a laboratory for analysis.<\/p>\n
Dr Lars Komorowski, chief scientific officer of EUROIMMUN, explained the significance: \u201cBecause there was no commercial assay for detecting anti-measles virus IgG antibodies using a DBS sample, diagnostic laboratories have had to validate DBS on their own. Now we can fill this gap by offering an IVDR-compliant solution.\u201d<\/p>\n<\/div><\/section>
\n
<\/span><\/span><\/div>
\n![\"\"](\"https:\/\/clinlabint.com\/wp-content\/uploads\/sites\/2\/2025\/03\/revvity_measles.jpg\" "\\"Screenshot\\"")
<\/div><\/div><\/div>
\n<\/span><\/span><\/div>
\nClinical and practical implications<\/h4>\n
The minimally invasive nature of DBS collection offers substantial advantages in multiple contexts:
\n\u2022 Routine clinical testing where venous blood collection may be challenging
\n\u2022 Research studies requiring simplified sample collection
\n\u2022 Regions with limited medical infrastructure
\n\u2022 Paediatric populations
\n\u2022 Remote or field-based surveillance efforts<\/p>\n
With measles cases increasing globally, expanding access to reliable testing supports broader surveillance and prevention strategies. The assay can be processed either manually or automatically using EUROIMMUN\u2019s scalable solutions for DBS processing and ELISA.<\/p>\n
Technical specifications<\/h4>\n
The Anti-Measles Virus ELISA 2.0 (IgG) is the first of several assays in development expanding EUROIMMUN\u2019s serological infection diagnostics portfolio with DBS validation. This approach eliminates the need for laboratories to perform in-house validation of DBS samples.<\/p>\n
About the company<\/h4>\n
Revvity provides health science solutions ranging from discovery to development and diagnosis to cure. The company focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, and informatics.<\/p>\n
For more information, visit: www.revvity.com<\/a>
\nDigital issue: Please click here<\/a> for more information<\/p>\n<\/div><\/section>
\n
Revvity\u2019s EUROIMMUN has received CE marking for its Anti-Measles Virus ELISA 2.0 (IgG), the first commercial assay validated for dried blood spot (DBS) sample material, addressing a critical gap in measles diagnostics as global cases continue to rise.<\/h3>\n
<\/p>\n
Innovation in sample collection<\/h4>\nThe newly launched Anti-Measles Virus ELISA 2.0 (IgG) represents a significant advancement in measles diagnostics, particularly for resource-limited settings. This IVDR-compliant solution supports both the diagnosis of measles virus infection and determination of immune status against the virus.<\/p>\n
The assay\u2019s key innovation lies in its validation for dried blood spots as a sample material, alongside conventional serum and plasma samples. DBS sampling requires only droplets of capillary blood from a fingertip, deposited onto a paper card, which can then be transported to a laboratory for analysis.<\/p>\n
Dr Lars Komorowski, chief scientific officer of EUROIMMUN, explained the significance: \u201cBecause there was no commercial assay for detecting anti-measles virus IgG antibodies using a DBS sample, diagnostic laboratories have had to validate DBS on their own. Now we can fill this gap by offering an IVDR-compliant solution.\u201d<\/p>\n<\/div><\/section>
\n
<\/span><\/span><\/div>
\n<\/div><\/div><\/div>
\n<\/span><\/span><\/div>
\nClinical and practical implications<\/h4>\n
The minimally invasive nature of DBS collection offers substantial advantages in multiple contexts:
\n\u2022 Routine clinical testing where venous blood collection may be challenging
\n\u2022 Research studies requiring simplified sample collection
\n\u2022 Regions with limited medical infrastructure
\n\u2022 Paediatric populations
\n\u2022 Remote or field-based surveillance efforts<\/p>\n
With measles cases increasing globally, expanding access to reliable testing supports broader surveillance and prevention strategies. The assay can be processed either manually or automatically using EUROIMMUN\u2019s scalable solutions for DBS processing and ELISA.<\/p>\n
Technical specifications<\/h4>\n
The Anti-Measles Virus ELISA 2.0 (IgG) is the first of several assays in development expanding EUROIMMUN\u2019s serological infection diagnostics portfolio with DBS validation. This approach eliminates the need for laboratories to perform in-house validation of DBS samples.<\/p>\n
About the company<\/h4>\n
Revvity provides health science solutions ranging from discovery to development and diagnosis to cure. The company focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, and informatics.<\/p>\n
For more information, visit: www.revvity.com<\/a>
\nDigital issue: Please click here<\/a> for more information<\/p>\n<\/div><\/section>
\n
\n
\n
<\/div><\/div><\/div>\n
\n
Clinical and practical implications<\/h4>\n
The minimally invasive nature of DBS collection offers substantial advantages in multiple contexts:
\n\u2022 Routine clinical testing where venous blood collection may be challenging
\n\u2022 Research studies requiring simplified sample collection
\n\u2022 Regions with limited medical infrastructure
\n\u2022 Paediatric populations
\n\u2022 Remote or field-based surveillance efforts<\/p>\n
With measles cases increasing globally, expanding access to reliable testing supports broader surveillance and prevention strategies. The assay can be processed either manually or automatically using EUROIMMUN\u2019s scalable solutions for DBS processing and ELISA.<\/p>\n
Technical specifications<\/h4>\n
The Anti-Measles Virus ELISA 2.0 (IgG) is the first of several assays in development expanding EUROIMMUN\u2019s serological infection diagnostics portfolio with DBS validation. This approach eliminates the need for laboratories to perform in-house validation of DBS samples.<\/p>\n
About the company<\/h4>\n
Revvity provides health science solutions ranging from discovery to development and diagnosis to cure. The company focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, and informatics.<\/p>\n
For more information, visit: www.revvity.com<\/a>
\nDigital issue: Please click here<\/a> for more information<\/p>\n<\/div><\/section>
\n